<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95867</article-id><article-id pub-id-type="doi">10.7554/eLife.95867</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.95867.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Human induced pluripotent stem cell-derived cardiomyocytes to study inflammation-induced aberrant calcium transient</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Tatekoshi</surname><given-names>Yuki</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7345-0158</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>Chunlei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Shapiro</surname><given-names>Jason Solomon</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0880-3142</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Hsiang-Chun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Blancard</surname><given-names>Malorie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Lyra-Leite</surname><given-names>Davi M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2929-5100</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Burridge</surname><given-names>Paul W</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Feinstein</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>D'Aquila</surname><given-names>Richard</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9653-5987</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Hsue</surname><given-names>Priscilla</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ardehali</surname><given-names>Hossein</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7662-0551</contrib-id><email>h-ardehali@northwestern.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000e0be47</institution-id><institution>Feinberg Cardiovascular and Renal Research Institute, Northwestern University</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000e0be47</institution-id><institution>Department of Pharmacology, Northwestern University</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000e0be47</institution-id><institution>Department of Medicine, Northwestern University</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Medicine, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mani</surname><given-names>Arya</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Harper</surname><given-names>Diane M</given-names></name><role>Senior Editor</role><aff><institution>University of Michiganâ€&quot;Ann Arbor</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>27</day><month>09</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP95867</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-01-17"><day>17</day><month>01</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-01-20"><day>20</day><month>01</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.01.17.575991"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-28"><day>28</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95867.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-09-04"><day>04</day><month>09</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95867.2"/></event></pub-history><permissions><copyright-statement>© 2024, Tatekoshi, Chen et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Tatekoshi, Chen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-95867-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-95867-figures-v1.pdf"/><abstract><p>Heart failure with preserved ejection fraction (HFpEF) is commonly found in persons living with HIV (PLWH) even when antiretroviral therapy suppresses HIV viremia. However, studying this condition has been challenging because an appropriate animal model is not available. In this article, we studied calcium transient in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in culture to simulate the cardiomyocyte relaxation defect noted in PLWH and HFpEF and assess whether various drugs have an effect. We show that treatment of hiPSC-CMs with inflammatory cytokines (such as interferon-γ or TNF-α) impairs their Ca<sup>2+</sup> uptake into sarcoplasmic reticulum and that SGLT2 inhibitors, clinically proven as effective for HFpEF, reverse this effect. Additionally, treatment with mitochondrial antioxidants (like mito-Tempo) and certain antiretrovirals resulted in the reversal of the effects of these cytokines on calcium transient. Finally, incubation of hiPSC-CMs with serum from HIV patients with and without diastolic dysfunction did not alter their Ca<sup>2+</sup>-decay time, indicating that the exposure to the serum of these patients is not sufficient to induce the decrease in Ca<sup>2+</sup> uptake in vitro. Together, our results indicate that hiPSC-CMs can be used as a model to study molecular mechanisms of inflammation-mediated abnormal cardiomyocyte relaxation and screen for potential new interventions.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>human induced pluripotent stem cell-derived cardiomyocyte</kwd><kwd>inflammation</kwd><kwd>calcium transient</kwd><kwd>human immunodeficiency virus</kwd><kwd>heart failure with preserved ejection fraction</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01 HL140973</award-id><principal-award-recipient><name><surname>Ardehali</surname><given-names>Hossein</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>SP0065527</award-id><principal-award-recipient><name><surname>Tatekoshi</surname><given-names>Yuki</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A calcium transient measurement system utilizing human induced pluripotent stem cell-derived cardiomyocytes reveals the detrimental impact of inflammatory cytokines on cardiomyocyte relaxation and displays the potential of drugs to reverse these defects.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Heart failure (HF) with preserved ejection fraction (HFpEF) refers to a form of HF that is associated with diastolic dysfunction (DD). On echocardiography, HFpEF is associated with a greater than 50% of blood in the left ventricle (LV) that is pumped with each beat but the LV displays impaired relaxation and increased stiffness during the filling phase of cardiac cycle. Echocardiographic evidence of DD is associated with higher all-cause mortality even in asymptomatic patients (<xref ref-type="bibr" rid="bib23">Kardys et al., 2009</xref>). The pathophysiology underlying DD is known to be an increase in the stiffness of the LV, although there are limited ways to study the mechanisms and interventions. Studies have shown that patients with HFpEF have multiple comorbidities, such as obesity, hypertension, renal dysfunction, and diabetes (<xref ref-type="bibr" rid="bib14">Dhingra et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Haass et al., 2011</xref>), and that it is associated with aging (<xref ref-type="bibr" rid="bib57">Xu and Daimon, 2016</xref>). It is also proposed that these comorbid conditions each lead to increased systemic inflammation, which then causes myocardial remodeling and fibrosis (<xref ref-type="bibr" rid="bib14">Dhingra et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Cheng et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Sanders-van Wijk et al., 2015</xref>; <xref ref-type="bibr" rid="bib49">Santhanakrishnan et al., 2012</xref>).</p><p>There are few options for the treatment of HFpEF, despite the increasing incidence of this disease in HIV-uninfected and -infected patients. The current treatments relieve symptoms and target comorbid conditions, such as hypertension, diabetes, coronary artery disease, hyperlipidemia, and atrial fibrillation. Although beta blockers, ACE inhibitors, angiotensin receptor blockers, and cardiac resynchronization therapy improve outcome in patients with HF with reduced ejection fraction, clinical benefits have scarcely been shown with any of these drugs in HFpEF. The only drugs that have shown clinical benefit in rigorous trials are antagonists of the mineralocorticoid receptor (such as spironolactone) (<xref ref-type="bibr" rid="bib43">Pfeffer and Braunwald, 2016</xref>), inhibitors of the sodium glucose co-transporter 2 (SGLT2, such as empagliflozin) (<xref ref-type="bibr" rid="bib2">Anker et al., 2021</xref>), and glucagon-like peptide 1 analog (such as semaglutide) (<xref ref-type="bibr" rid="bib28">Kosiborod et al., 2023</xref>).</p><p>Persons living with HIV (PLWH) have a higher prevalence of HFpEF compared to uninfected individuals (<xref ref-type="bibr" rid="bib38">Meng et al., 2002</xref>; <xref ref-type="bibr" rid="bib50">Schuster et al., 2008</xref>). Recent studies have shown that LV mass index and DD are each significantly worse in PLWH with HFpEF than among persons living without HIV with HFpEF, despite similar EF. These features were associated with lower nadir CD4<sup>+</sup> T-cell count, suggesting that this process could be due to the level of immunodeficiency and/or duration of untreated infection (<xref ref-type="bibr" rid="bib19">Hsue et al., 2010</xref>). Several studies attempted to determine the mechanism for increased HFpEF in PLWH. Administration of HIV gp120 resulted in DD after adrenergic stimulation in rats (<xref ref-type="bibr" rid="bib6">Berzingi et al., 2009</xref>) and caused negative inotropic effects in adult rat ventricular myocytes (<xref ref-type="bibr" rid="bib22">Kan et al., 2004</xref>; <xref ref-type="bibr" rid="bib59">Yuan et al., 2008</xref>). Macaques infected with simian immunodeficiency virus (SIV) display DD, which was associated with the degree of myocardial SIV viral load. Inhibition of CCR5, a co-receptor with CD4 for HIV gp120-mediated entry into cells, in the SIV-infected rhesus macaque model of DD preserved cardiac diastolic function (<xref ref-type="bibr" rid="bib26">Kelly et al., 2014</xref>).</p><p>Untreated HIV infection is associated with circulating inflammatory cytokines and chemokines (<xref ref-type="bibr" rid="bib24">Katsikis et al., 2011</xref>), and many remain elevated even when HIV viremia is well-controlled by antiretroviral therapy (ART) (<xref ref-type="bibr" rid="bib25">Keating et al., 2011</xref>; <xref ref-type="bibr" rid="bib44">Ramirez et al., 2014</xref>). For instance, elevated IFN-γ is observed during acute HIV viremia and remained elevated despite highly active ART (HAART) (<xref ref-type="bibr" rid="bib46">Roff et al., 2014</xref>). Higher IFN-γ is also associated with impaired CD4 recovery in HIV after the initiation of HAART (<xref ref-type="bibr" rid="bib56">Watanabe et al., 2019</xref>). Additionally, while the immune system resets itself after the regression of bacterial or viral infection, it remains hypersensitive when ART suppresses viremia in chronic HIV infection. Of note, monocytes from PLWH treated with viremia suppressing ART demonstrated increased production of TNF-α and IL-6 after stimulation with lipopolysaccharide (<xref ref-type="bibr" rid="bib1">Amirayan-Chevillard et al., 2000</xref>), indicating the presence of immune system rewiring during HIV infection that is not reversed with effective ART. Therefore, cardiomyocytes in PLWH are exposed to higher circulating inflammatory cytokines at baseline despite effective ART, and with further elevation of these inflammatory cytokines after concomitant infections. Among these cytokines, TNF-α is associated with mortality (<xref ref-type="bibr" rid="bib54">Wada et al., 2016</xref>) and severe coronary stenosis (greater than 70% stenosis) <xref ref-type="bibr" rid="bib4">Bahrami et al., 2016</xref> in PLWH.</p><p>There are limited studies to address the molecular basis of cardiomyocyte dysfunction in HIV-mediated HFpEF or the effectiveness of various drugs. Additionally, there are currently no models using human heart cells and HIV. These major limitations raise the critical need for a novel approach to study this complicated disease. Human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (hiPSC-CM) represent a novel technology that has been successfully applied to understanding basic mechanisms of several cardiovascular diseases, including long QT (<xref ref-type="bibr" rid="bib20">Itzhaki et al., 2011</xref>), LEOPARD (<xref ref-type="bibr" rid="bib8">Carvajal-Vergara et al., 2010</xref>) and Timothy (<xref ref-type="bibr" rid="bib58">Yazawa et al., 2011</xref>) syndromes, dilated cardiomyopathy (CM) (<xref ref-type="bibr" rid="bib53">Sun et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Lan et al., 2013</xref>), and hypertrophic CM (<xref ref-type="bibr" rid="bib30">Lan et al., 2013</xref>). They are also used for efficacy and toxicity screening of drugs (<xref ref-type="bibr" rid="bib34">Liang et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Navarrete et al., 2013</xref>), leading to enhanced understanding of cellular mechanisms at the single cardiomyocyte level, not previously possible using human cells. Furthermore, hiPSC-CMs have been used to study a model of viral myocarditis (i.e., coxsackie virus) and predict the efficacy of antiviral drug therapies (<xref ref-type="bibr" rid="bib51">Sharma et al., 2014</xref>), indicating that these cells can be used to study HF due to viral infections. In this article, we show that hiPSC-CMs can be used as a model for the assessment of calcium transient in response to inflammatory cytokines in vitro and to assess the effects of various drugs on their relaxation parameters. Given the major limitations in the field of HIV-mediated cardiac dysfunction, this model will allow investigators to study the mechanism of cardiac DD in inflammatory condition in vitro and assess the effectiveness of various drugs to reverse impaired relaxation noted with systemic inflammation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TNF-α and IFN-γ impair relaxation in hiPSC-CMs without causing cellular damage</title><p>We first generated hiPSCs and differentiated into cardiomyocytes using the protocols previously published by our groups (<xref ref-type="bibr" rid="bib7">Burridge et al., 2015</xref>). Successful production of hiPSC-CMs was confirmed by the assessment of their morphology and calcium transient property (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>, <xref ref-type="video" rid="fig1video1">Figure 1—video 1</xref>). We then assessed whether treatment with cytokines would have detrimental effects on these cells. Because DD has been associated with mitochondrial dysfunction (<xref ref-type="bibr" rid="bib29">Kumar et al., 2019</xref>), we first measure whether cytokine treatment results in changes in mitochondrial membrane potential (MMP) at baseline. For these experiments, cells were treated with cytokines at indicated concentrations for 48 hr. These studies revealed that each of the cytokines studied in our system did not alter MMP in hiPSC-CMs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). For the remaining studies, we focused our experiments on two of these cytokines that often are chronically increased in PLWH, TNF-α, and IFN-γ.</p><p>We next assessed whether treatment with TNF-α or IFN-γ alters diastolic function in hiPSC-CMs by measuring calcium transient and assessing the decay time and downstroke time in these cells using Single Cell Kinetic Image Cytometry (Vala Sciences). Treatment with both TNF-α and IFN-γ resulted in a significant increase in decay time and downstroke time, which are markers of cardiomyocyte relaxation, while beats per minute (indirect measurement of heart rate and not diastolic function) was essentially unchanged (<xref ref-type="fig" rid="fig1">Figure 1A–C</xref>). Additionally, treatment with mito-Tempo (an agent with mitochondrial antioxidant activity) reversed the changes that occurred with TNF-α (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>), indicating that a reduction in mitochondrial reactive oxygen species (ROS) may, at least partially, reverse the cardiomyocyte relaxation defect induced by TNF-α.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Analyses of calcium transient in hiPSC-CMs treated with cytokines and/or MitoTempo.</title><p>Normalized downstroke time (<bold>A</bold>), decay time (<bold>B</bold>), and beating rate as assessed by beats per minute (<bold>C</bold>) in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) treated with bovine serum albumin (BSA), (control), TNF-α, IFN-γ, TNF-α plus mito-Tempo, and IFN-γ plus mito-Tempo. N = 5–14. Data were analyzed by ordinary one-way ANOVA and post hoc Tukey’s multiple-comparison test. Bars represent group mean, and error bars indicate standard error of the mean.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Analyses of calcium transient in hiPSC-CMs treated with cytokines and/or MitoTempo.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>A representative calcium transient curve in hiPSC-CMs and their mitochondrial potential.</title><p>(<bold>A</bold>) Representative image of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM). Scale bar represents 100 μm. (<bold>B</bold>) Representative curves of calcium transient and its derivative in hiPSC-CM. (<bold>C</bold>) Mitochondrial membrane potential (MMP) as assessed by tetramethylrhodamine ethyl ester (TMRE) in hiPSC-CM treated with various cytokines. Concentration of cytokines used is as follows: CCL3 1 nM, TNF-α 300 pg/ml, IL-6 1 ng/ml, IL-1β 200 pg/ml, IP-10 (or CXCL10) 500 pg/ml, IFN-γ 1 ng/ml. N = 4, Data were analyzed by ordinary one-way ANOVA and post hoc Tukey’s multiple-comparison test. Bars represent group mean , and error bars indicate standard error of the mean.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>A epresentative image of hiPSC-CMs, a calcium transient curve, and a relative dF/dt curve.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Relative TMRE fluorescence in hiPSC-CMs with cytokine treatments.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig1-figsupp1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig1-figsupp1-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-95867-fig1-video1.mp4" id="fig1video1"><label>Figure 1—video 1.</label><caption><title>Representative video of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) contracting spontaneously in a culture dish.</title><p>Scale bar represents 100 μm.</p></caption></media></fig-group><p>Since mito-Tempo partially reversed the effects of TNF-α on calcium transient of hiPSC-CMs, we next assessed whether TNF-α and IFN-γ have any effects on mitochondrial respiration and whether these potential defects would be reversed with antioxidants. For these experiments, we used Seahorse XF96 Analyzer to measure the oxygen consumption rate (OCR) after treatment with TNF-α or IFN-γ in the presence and absence of the general antioxidant, N-acetylcysteine (NAC). While both TNF-α and IFN-γ did not induce significant changes in OCR, administration of NAC to hiPSC-CMs supplemented with TNF-α significantly reduced OCR at baseline (<xref ref-type="fig" rid="fig2">Figure 2</xref>). These data indicate that the beneficial effects of antioxidant reagents on calcium transient might be associated with the alleviation of aberrantly regulated OCR in TNF-α-treated cells. We next used this platform to study the effects of various drugs on in vitro measures of DD.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Oxygen consumption rate (OCR) in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) treated with cytokines and antioxidant agent N-acetylcysteine (NAC).</title><p>(<bold>A</bold>) OCR trace of hiPSC-CM treated with bovine serum albumin (BSA), TNF-α, IFN-γ, TNF-α + IFN-γ, TNF-α + NAC, IFN-γ + NAC, and TNF-α + IFN-γ + NAC. (<bold>B–D</bold>) Bar graph summary of data in (<bold>A</bold>) with OCR at baseline (<bold>B</bold>), after adding carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (<bold>C</bold>), and after adding antimycin A and rotenone (<bold>D</bold>). N = 5–6. Data were analyzed by ordinary one-way ANOVA and post hoc Tukey’s multiple-comparison test. Bars represent group mean, and error bars indicate standard error of the mean.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>OCR curve in hiPSCs treated with cytokines and NAC.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>OCR at baseline, after CCCP treatment and after rotenone and antimycin A treatment.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig2-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig2-v1.tif"/></fig></sec><sec id="s2-2"><title>Certain antiviral drugs and SGLT2 inhibitors reverse impaired relaxation in hiPSC-CMs</title><p>Given that we were able to induce impaired relaxation indicated by aberrant Ca<sup>2+</sup> uptake in hiPSC-CMs after treatment with inflammatory cytokines, we assessed whether various antiretrovirals and other drugs that potentially target the pathogenesis of HFpEF can reverse the dysregulation of calcium transient in vitro. We first assessed whether ART drugs at various concentrations cause cell death or increased ROS production in hiPSC-CMs. We treated hiPSC-CMs with tenofovir (a nucleotide-analog reverse transcriptase inhibitor), darunavir (a protease inhibitor), raltegravir, and elvitegravir (integrase inhibitors) at concentrations between 3 µM and 10 mM. The dose range was chosen to extend to tenfold above the IC50 concentrations and reflects the upper range of circulating drug concentration in patients receiving these medications (<xref ref-type="bibr" rid="bib15">Droste et al., 2005</xref>; <xref ref-type="bibr" rid="bib21">Kakuda et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Shiomi et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Wang et al., 2011</xref>). In this dose range, we did not observe apparent changes in cell viability and cellular ROS levels (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>), indicating that exposure to these single drugs alone has minimal effects on cell survival.</p><p>We then assessed whether ART can reverse the impaired relaxation induced by TNF-α. For these studies, we used the following single drug concentrations: 5 µM tenofovir, 10 µM darunavir, 3 µM raltegravir, and 10 µM emtricitabine (an HIV nucleoside analog reverse transcriptase inhibitor). As shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>, while TNF-α increased the decay time in hiPSC-CMs, treatment with tenofovir, darunavir, raltegravir, and emtricitabine reversed these effects. These results indicate that ART may have beneficial effects on the inflammation-mediated deterioration of calcium transient that occurs in HIV patients, raising the possibility that its potential benefits may go beyond their inhibitory effects on the virus itself.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Decay time in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) after treatment with TNF-α and various antiretroviral therapy (ART) drugs.</title><p>(<bold>A</bold>) Decay time after treatment with TNF-α, tenofovir, and TNF-α+tenofovir. (<bold>B</bold>) Decay time after treatment with TNF-α, darunavir, and TNF-α+darunavir. (<bold>C</bold>) Decay time after treatment with TNF-α, raltegravir, and TNF-α + raltegravir. (<bold>D</bold>) Decay time after treatment with TNF-α, emtricitabine, and TNF-α + emtricitabine. N = 5–21. Data were analyzed by ordinary one-way ANOVA and post hoc Tukey’s multiple-comparison test. Bars represent group mean, and error bars indicate standard error of the mean.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Normalized decay times in hiPSC-CMs treated with TNF-α and/or anti-HIV drugs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Cell viability and ROS levels in hiPSC-CMs treated with anti-HIV drugs.</title><p>Cell viability (<bold>A</bold>) and cellular reactive oxygen species (ROS) levels (<bold>B</bold>) in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) exposed to concentrations ranging from between 3 nM and 10 μM of tenofovir (a nucleotide-analog reverse transcriptase inhibitor), darunavir (a protease inhibitor), raltegravir, and elvitegravir (integrase inhibitors). N=1-6.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Cell viability and ROS levels in hiPSC-CMs treated with anti-HIV drugs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig3-figsupp1-v1.tif"/></fig></fig-group><p>A number of other drugs have also been proposed to potentially exert beneficial effects in HFpEF. Among these, we focused on an oral soluble guanylate cyclase stimulator (riociguat,1 µM), a phosphodiesterase (PDE)-5 inhibitor (sildenafil, 1 µM), a PDE9 inhibitors (PF-04447943, 5 µM), and an SGLT2 inhibitor (dapagliflozin, 10 µM). The dosages are based on previous functional studies in isolated cardiomyocytes (<xref ref-type="bibr" rid="bib9">Castro et al., 2006</xref>; <xref ref-type="bibr" rid="bib27">Kiso et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Lee et al., 2015</xref>; <xref ref-type="bibr" rid="bib45">Reinke et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Zhang et al., 2006</xref>). Specifically, we also tested 1 µM of dapagliflozin and found no effects on decay and downstroke times (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>). While TNF-α caused a significant increase in decay time in hiPSC-CMs, riociguat, sildenafil, and PF-04447943 failed to reverse this effect (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>), indicating that they do not have the properties to reverse the inflammation-mediated impaired relaxation. However, SGLT2 inhibitor dapagliflozin significantly reversed the prolonged decay and downstroke times induced by TNF-α in hiPSC-CMs (<xref ref-type="fig" rid="fig4">Figure 4D–G</xref>). Additionally, we repeated the experiments with IFN-γ and dapagliflozin and showed that the drug was able to reverse the increased decay and downstroke time associated with IFN-γ as well (<xref ref-type="fig" rid="fig4">Figure 4H–K</xref>). These studies are in accordance with the clinical studies that have shown beneficial effects of SGLT2 inhibitors in HFpEF and suggest that they may also benefit patients with inflammation-induced aberrant calcium transient, like HIV+ patients.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Decay time in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) after treatment with TNF-α and riociguat, sildenafil citrate, PF-04447943, and dapagliflozin.</title><p>(<bold>A</bold>) Decay time after treatment with TNF-α, sGS agonist riociguat, and TNF-α + riociguat (N = 8–21). (<bold>B</bold>) Decay time after treatment with TNF-α, sildenafil citrate, and TNF-α + sildenafil citrate (N = 5–21). (<bold>C</bold>) Decay time after treatment with TNF-α, PF-04447943, and TNF-α+PF-04447943 (N = 7–21). (<bold>D</bold>) Representative curve of calcium transient in hiPSC-CM treated with TNF-α, dapagliflozin, and TNF-α + dapagliflozin. (<bold>E</bold>) Curve of derivative calculated with data in (<bold>D</bold>). (<bold>F</bold>) Decay time after treatment with TNF-α, dapagliflozin, and TNF-α+dapagliflozin (N = 5–21). (<bold>G</bold>) Downstroke time after treatment with TNF-α, dapagliflozin, and TNF-α + dapagliflozin(N = 5–21). (<bold>H</bold>) Representative curve of calcium transient in hiPSC-CM treated with IFN-γ, dapagliflozin, and IFN-γ + dapagliflozin. (<bold>I</bold>) Curve of derivative calculated with data in (<bold>H</bold>). (<bold>J</bold>) Decay time after treatment with INF-γ, dapagliflozin, and IFN-γ + dapagliflozin (N = 5–21). (<bold>K</bold>) Downstroke time after treatment with INF-γ, dapagliflozin, and IFN-γ + dapagliflozin (N = 5–21). Data were analyzed by ordinary one-way ANOVA and post hoc Tukey’s multiple-comparison test. Bars represent group mean, and error bars indicate standard error of the mean.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Normalizaed decay times in hiPSC-CMs treated with TNFα and Riociguat, Sildenafil citrate and PF-04447943.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Analyses of calcium transient in hiPSC-CMs treated with TNFα, INFγ and 10 μM Dapagliflozin.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig4-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Analyses of calcium transient in hiPSC-CMs treated with TNFa and/or 1 μM Dapagliflozin.</title><p>Decay time (<bold>A</bold>) and downstroke time (<bold>B</bold>) in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) after treatment with TNF-α and 1 μM of dapagliflozin.</p><p>N = 5–21, Data were analyzed by ordinary one-way ANOVA and post hoc Tukey’s multiple-comparison test. Bars represent group mean, and error bars indicate standard error of the mean.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Treatment with serum from patients with HIV does not induce impaired relaxation in hiPSC-CMs</title><p>Given that we could simulate impaired calcium transient in hiPSC-CMs using inflammatory cytokines, we next assessed whether short-term treatment of these cells with serum from HIV+ patients with evidence of DD would also induce impaired Ca<sup>2+</sup> uptake in the cells. We used two sources of serum in our studies. For the first group, we recruited six men with chronic HIV on ART with undetectable viral loads who underwent cardiac magnetic resonance imaging (CMRI) at the Northwestern Memorial Hospital (NMH) for the assessment of myocardial perfusion reserve (MPR). Clinical and MRI-based characteristics of these patients are included in <xref ref-type="table" rid="table1">Table 1</xref>. Lower values of MPR indicate impaired global myocardial blood flow in response to vasodilator stress and are associated with higher incidence of HFpEF and poor prognosis (<xref ref-type="bibr" rid="bib3">Arnold et al., 2022</xref>; <xref ref-type="bibr" rid="bib37">Markley et al., 2023</xref>). The second group included well-controlled patients with HIV at University of California San Francisco (UCSF) with echocardiographic evidence of normal cardiac function or DD.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Clinical characteristics of study population for group 1.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Participant</th><th align="left" valign="bottom">Age</th><th align="left" valign="bottom">High or low myocardial perfusion reserve group</th><th align="left" valign="bottom">Sex</th><th align="left" valign="bottom">CD4 count</th><th align="left" valign="bottom">Diabetes mellitus?</th><th align="left" valign="bottom">Active cigarette smoking?</th><th align="left" valign="bottom">Hypertension?</th><th align="left" valign="bottom">Coronary artery disease diagnosis?</th><th align="left" valign="bottom">Left ventricular ejection fraction</th><th align="left" valign="bottom">Myocardial perfusion reserve</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">50</td><td align="left" valign="bottom">High</td><td align="left" valign="bottom">Male</td><td align="char" char="." valign="bottom">487</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="char" char="." valign="bottom">64</td><td align="char" char="." valign="bottom">2.74</td></tr><tr><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">62</td><td align="left" valign="bottom">Low</td><td align="left" valign="bottom">Male</td><td align="char" char="." valign="bottom">703</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">59</td><td align="char" char="." valign="bottom">1.03</td></tr><tr><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">64</td><td align="left" valign="bottom">High</td><td align="left" valign="bottom">Male</td><td align="char" char="." valign="bottom">321</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">65</td><td align="char" char="." valign="bottom">3.43</td></tr><tr><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">55</td><td align="left" valign="bottom">High</td><td align="left" valign="bottom">Male</td><td align="char" char="." valign="bottom">749</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">59</td><td align="char" char="." valign="bottom">1.90</td></tr><tr><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">71</td><td align="left" valign="bottom">Low</td><td align="left" valign="bottom">Male</td><td align="char" char="." valign="bottom">1743</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">55</td><td align="char" char="." valign="bottom">1.03</td></tr><tr><td align="char" char="." valign="bottom">6</td><td align="char" char="." valign="bottom">59</td><td align="left" valign="bottom">Low</td><td align="left" valign="bottom">Male</td><td align="char" char="." valign="bottom">678</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="char" char="." valign="bottom">52</td><td align="char" char="." valign="bottom">1.13</td></tr></tbody></table></table-wrap><p>For both groups, we treated hiPSC-CMs with 10% serum from these patients for 48 hr, followed by the measurement of calcium transients. Additionally, we treated human umbilical vein endothelial cells (HUVEC) with the serum of these patients for 20 hr and assessed their angiogenic potential given the critical relationship between endothelial dysfunction and the development of HFpEF (<xref ref-type="bibr" rid="bib12">Cornuault et al., 2022</xref>; <xref ref-type="bibr" rid="bib42">Paulus and Tschöpe, 2013</xref>). For the first group of patients, we stratify into higher (1.9–3.4; N = 3) versus lower (1.0–1.1; N = 3) MPR values, which correspond to control and DD, respectively. As shown in <xref ref-type="fig" rid="fig5">Figure 5A–C</xref>, serum from HIV+ patients with DD from group 1 did not result in a significant change in decay and downstroke time in hiPSC-CMs. Similar results were obtained after 24 hr incubation. Additionally, serum from these patients did not alter the tube network formation of HUVECs (<xref ref-type="fig" rid="fig5">Figure 5D–G</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref> and <xref ref-type="fig" rid="fig5s2">2</xref>). We also assessed the effects of serum from HIV+ patients from group 2. The control group for experiments included serum from HIV patients without evidence of DD. Our data indicate that the treatment of hiPSC-CMs and HUVECs with 2% serum of these patients for 3 or 24 hr does not alter decay time (<xref ref-type="fig" rid="fig6">Figure 6A–D</xref>) and tube formation capacity (<xref ref-type="fig" rid="fig6">Figure 6E–I</xref>), respectively. For hiPSC-CMs studies, we exposed the cells to serum for 3 hr and 24 hr and did not observe a difference in decay time with either time point. These results suggest that short treatment of hiPSC-CMs or HUVECs with serum from patients with DD does not induce changes in calcium transient or their angiogenic potential, respectively.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Ca<sup>2+</sup>-decay time of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and angiogenic function of ECs after treatment with serum from group 1 HIV+ patients with diastolic dysfunction (DD).</title><p>(<bold>A–C</bold>) Pooled normalized decay time (<bold>A</bold>), downstroke time (<bold>B</bold>), and beating rate (<bold>C</bold>) in hiPSC treated with 10% serum for 48 hr from group 1 HIV+ patients with DD (3 values from cells treated with each serum). (<bold>D–G</bold>) Angiogenic parameters, including total length of branching (<bold>D</bold>) (N = 3), number of junctions (<bold>E</bold>) (N = 3), total length (<bold>F</bold>) (N = 3), and number of meshes (<bold>G</bold>) (N = 3) in human umbilical vein endothelial cells (HUVEC) after treatment with 2% serum from group 1 patients for 20 hr. Data were analyzed by unpaired Student’s <italic>t</italic>-test. Bars represent group mean, and error bars indicate standard error of the mean.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Analyses of calcium transient in hiPSCs treated with serum from HIV patients.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Quantitative analyses of tube formation assay in HUVECs treated with serum from HIV patients.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig5-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Representative images of formed tube structure with human umbilical vein endothelial cells (HUVEC) treated with 2% serum from HIV+ patients with high or low myocardial perfusion reserve (MPR) for 20 hr.</title><p>Scale bars represent 500 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Representative magnified images of formed tube structure with human umbilical vein endothelial cells (HUVEC) treated with 2% serum from HIV+ patients with high or low myocardial perfusion reserve (MPR) for 20 hr.</title><p>Scale bars indicate 250 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig5-figsupp2-v1.tif"/></fig></fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Diastolic function of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and angiogenic function of ECs after treatment with serum from HIV+ patients with diastolic dysfunction (DD) (group 2).</title><p>(<bold>A, B</bold>) Individual normalized decay time 3 hr (N = 3–9) (<bold>A</bold>) or 24 hr (N = 3–13) (<bold>B</bold>) after treatment of hiPSC-CM with 2% serum from patients. (<bold>C, D</bold>) Pooled decay time data from patients in (<bold>A</bold>) and (<bold>B</bold>) with 3 hr (<bold>C</bold>) and 24 hr (<bold>D</bold>) after treatment with serum (N = 21–22 for (<bold>C</bold>) and N = 31-38 for (<bold>D</bold>)). (<bold>E</bold>) Representative image of formed tube structure with cultured human umbilical vein endothelial cells (HUVEC) treated with serum from HIV+ patients with DD. Scale bars indicate 250 μm. (<bold>F–I</bold>) Assessment of tube formation of HUVECs 20 hr after treatment with serum of patients, including number of meshes (<bold>F</bold>) (N = 8), number of junctions (<bold>G</bold>) (N = 8), number of segments (<bold>H</bold>) (N = 8), and total length of branching (<bold>I</bold>) (N = 8). Data were analyzed by unpaired Student’s <italic>t</italic>-test for (<bold>C, D, F, G, H, I</bold>). Bars represent group mean, and error bars indicate standard error of the mean.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Normalized decay time in iPS-CMs treated with HIV patient serum with or without diastolic dysfunction.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig6-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Quantitative analyses of tube formation assay in HUVECs treated with serum from HIV patients.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95867-fig6-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95867-fig6-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>HFpEF is a common disease and its incidence continues to increase. Among the risk factors for HFpEF, inflammation is believed to be a common mechanism for the development of the disease. The chronic inflammatory condition associated with treated HIV infection is believed to be responsible for the development of HFpEF in these patients. Despite the high incidence of this disorder among the general population and those with HIV, there are currently very few systems available to study this disorder and screen for drugs that can target the disease. In this article, we used hiPSC-CMs as a platform to assess whether abnormal cardiomyocyte relaxation can be induced in these cells in response to inflammatory cytokines. We demonstrate that TNF-α and IFN-γ can induce prolonged decay time in hiPSC-CMs, which can partially be reversed with mitochondrially targeted antioxidants. We also demonstrate that most ART drugs and SGLT2 inhibitors can reverse the aberrant calcium transient associated with inflammatory cytokines. Finally, to determine whether treatment of hiPSC-CMs serum from patients with HIV and DD can also induce deterioration of calcium transient in hiPSC-CMs, we treated these cells with patient serum, but were not able to mimic DD. We also assessed whether serum from these patients can induce defects in angiogenic potential and found no effects on these parameters. Overall, our results provide a novel platform to study dysregulated calcium transient associated with inflammatory cytokine treatment and test the effectiveness of various agents in this disorder.</p><p>Studying HFpEF in tissue culture has its own limitations since HFpEF is a systemic disorder and usually develops as a result of a number of risk factors, including diabetes, hypertension, and chronic kidney disease. It is important to note that DD is a major component of HFpEF and studying the relaxation abnormalities associated with this disorder, especially in tissue culture setting, can provide major clues to this disease at the cellular level. Thus, using a cell culture system to mimic the functional abnormality noted in this disorder can provide clues to the disease that can later be tested at the organismal level. Given that there are limited animal models for HFpEF, an in vitro model will provide a powerful platform for hypothesis generation and drug screening prior to committing resources for studying these findings at the organismal level.</p><p>We demonstrated that treatment with certain cytokines can induce prolonged decay time in hiPSC-CMs, but serum from HIV patients with imaging evidence of DD did not cause similar abnormalities. This could be due to several reasons, including short duration of the treatment with human serum, lower concentration of cytokines in the serum compared to the concentration we used in our studies, and possibly differences in gene expression patterns between human matured cardiomyocytes and hiPSC-CMs. In fact, previous studies demonstrated lower concentrations of TNF-α and IFN-γ (41.32 pg/ml and 0.78 pg/ml, respectively) in HIV+ patient serum than ones adopted in this study (<xref ref-type="bibr" rid="bib39">Musa et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">Osuji et al., 2018</xref>). Because of the limited availability of serum samples from HIV patients, we were not able to test different concentration and duration of serum treatment in our hiPSC-CM system. Further experiments with serum from HIV+ with DD in a large scale are warranted to determine whether other conditions can induce aberrant calcium transient. Nevertheless, it is important to note that cytokines alone can induce impaired Ca<sup>2+</sup> uptake in hiPSC-CMs and can be used to induce this condition in vitro.</p><p>It is surprising that SGLT2 inhibitors reversed the progression of DD in our system since cardiomyocytes do not express SGLT2 under physiological conditions. Interestingly, Marfella et al. reported that adult cardiomyocytes express SGLT2 in diabetic conditions (<xref ref-type="bibr" rid="bib36">Marfella et al., 2022</xref>). Since diabetes is associated with low-grade systemic inflammation, HIV patients might also express SGLT2 in their cardiomyocytes. Taken together, our data indicate that SGLT2 inhibitors at the dosages used in this study reverse the impaired calcium transients induced by TNF-α and IFN-γ. Additionally, the fact that ART drugs were able to reverse the impaired Ca<sup>2+</sup> uptake associated with cytokine treatment raises the possibility that these drugs can prevent damage to cardiomyocyte function as a result of the inflammation associated with HIV, in addition to their anti-retroviral effects.</p><p>There are limitations to our studies. Although decay and downstroke time were utilized as surrogates of cardiomyocyte relaxation, direct biomechanical characterization of contraction was not conducted in our study. While cytosolic calcium concentration is a major factor in the regulation of cellular relaxation (<xref ref-type="bibr" rid="bib17">Feridooni et al., 2015</xref>), certain conditions, including the transition of sarcomere protein isoforms to pathogenic ones (<xref ref-type="bibr" rid="bib16">Fentzke et al., 1999</xref>) and stimulation of β-adrenergic receptors (<xref ref-type="bibr" rid="bib5">Bers et al., 2019</xref>), can alter this relationship. However, since hiPSC-CMs utilized for each study are from iPS cells derived from a single donor, we believe that these parameters had minimal effects on our system. We also did not elucidate the molecular mechanisms underlying prolonged decay time induced by TNF-α and IFN-γ. TNF-α treatment is reported to induce a longer decay of calcium transient and a decreased sarcoplasmic ATPase (SERCA) expression in rabbit cardiomyocytes from pulmonary vein (<xref ref-type="bibr" rid="bib31">Lee et al., 2007</xref>) Thus, our observation in hiPSC-CMs may also be through decreased expression of SERCA though further studies remain conducted. Darunavir is generally used in combination with ritonavir and elvitegravir along with cobicistat in clinical practice. These additional drugs were not tested in our studies. Additionally, our studies employed only single drugs, which is not commonly used in the clinic. Also. we did not perform a dose–response curve with the drugs we tested, but used concentrations that were reported previously. Another limitation of our study is that we did not determine the mechanism of how ART drugs with such different effects on HIV proteins can have an effect on cellular relaxation. This is an important issue, and further studies are needed to better assess the mechanism of how ART can exert such effects.</p><p>In summary, we provide a novel approach to study inflammation-induced calcium transient at the cellular level using hiPSC-CMs. We use this method to test a number of drugs and whether they can reverse the prolonged decay time associated with inflammation. This system can prove useful in studying the molecular basis and potential treatments for HFpEF induced by chronic inflammation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Human induced pluripotent cell derivation and cardiac differentiation</title><p>Protocols and consents were approved by the institutional review board of Northwestern University (STU00204341). The hiPSC from healthy individuals was generated following the protocol published before (<xref ref-type="bibr" rid="bib11">Churko et al., 2013</xref>). Identity of hiPSC was authenticated by the confirmation of karyotype, gene expression, and undifferentiated cell marker expression (<xref ref-type="bibr" rid="bib35">Lyra-Leite et al., 2023</xref>). All cultures were routinely tested for mycoplasma using a MycoAlert PLUS Kit (Lonza, LT07-710) and a Varioskan LUX (Thermo) plate reader. The hiPSC were maintained and differentiated into beating cardiomyocytes, according to the previously published protocol (<xref ref-type="bibr" rid="bib7">Burridge et al., 2015</xref>).</p></sec><sec id="s4-2"><title>Cell line</title><p>HUVECs were purchased from Lonza (#C2519A) and subsequently used in our experiments. The cell identity was authenticated by the vender, confirming double-positive expression for CD31 and CD105. According to the certificate of analyses provided by the vender, the cells tested negative for mycoplasma, and all cultures were routinely tested for mycoplasma as well.</p></sec><sec id="s4-3"><title>MMP measurement</title><p>Media was removed from hiPSC-CM and were washed with phosphate-buffered saline (PBS) and FluoroBrite DMEM (no glutamine, no HEPES, no phenol red, no sodium pyruvate, Thermo A1896702) was added. Cells were stained with 5 nM TMRE (for mitochondrial stain) for 20 min and then washed with PBS before immunofluorescence. TMRE (red channel) signal was analyzed as MMP using ImageJ (Fiji).</p></sec><sec id="s4-4"><title>Seahorse assay</title><p>7 days before assay, hiPSC-CMs were plated at 100,000 cells per well in Matrigel-coated Seahorse XF cell culture 96-well plate. The day before the assay, the Seahorse cartridge was placed in the XF calibrant and incubated overnight at 37°C. On the day of the assay, the plates were incubated at room temperature for 1 hr in glucose-free complete DMEM or RPMI without bicarbonate or phenol red to allow even distribution of cells across the well floor. Before placing the sample plates in the Seahorse XF96 Analyzer, media volume was adjusted to 150 µl in each well. 25 mM glucose, 1.5 mM oligomycin, 1 µM CCCP, and 20 µM rotenone (Rot)/antimycin A (AA) were diluted in DMEM and injected sequentially into each well, following the standard Seahorse protocol. Cytokine treatment was started 48 hr before Seahorse assay.</p></sec><sec id="s4-5"><title>Treatment of hiPSC with IFN-γ and TNF-α</title><p>hiPSC-CMs after 21–24 days culturing were seeded into 6-well or 96-well cell culture plates. After 5 days, IFN-γ at 1 ng/ml and TNF-α at 300 pg/ml were added to the cells for 48 hr.</p></sec><sec id="s4-6"><title>Drug concentrations</title><p>We used the following drug concentrations for our studies: riociguat 1 µM, sildenafil citrate 1 µM, PF-04447943 5 µM, dapagliflozin 1 or 10 µM, tenofovir 5 µM, emtricitabine 10 µM, darunavir 10 µM, and raltegravir 3 µM.</p></sec><sec id="s4-7"><title>Calcium transient studies in hiPSC-CM</title><p>For Ca<sup>2+</sup> transient analysis, day 21–24 hiPSC-CMs were plated on the Matrigel-coated 96-well black cell culture plate at a density of 75,000 cells/well. Calcium imaging was performed as described previously (<xref ref-type="bibr" rid="bib47">Romero-Tejeda et al., 2023</xref>). On the day of imaging (days 28–32), cells were stained with a buffer containing 5 µM Fluo-4AM, NucBlue (2 drops/10 ml), 2.5 mM probenecid, 0.02% Pluronic F-127 in FluoroBrite DMEM for 1 hr at 37°C, 5% CO<sub>2.</sub> After 1 hr incubation, aspirate dye loading solution and add 200 µl FluoroBrite DMEM to each well for imaging. Single Cell Kinetic Image Cytometry (Vala Sciences) was used to scan the plate and CyteSeer Automated Video Analysis Software (Vala Sciences) was used to analyze the Ca<sup>2+</sup> transient.</p></sec><sec id="s4-8"><title>Tube formation assay</title><p>The formation of tube networks was assessed as described before (<xref ref-type="bibr" rid="bib13">Das et al., 2018</xref>). HUVECs were seeded at 20,000 per well in a 96-well plate coated with 75 ml Matrigel (Fisher Scientific) or Cultrex (R&amp;D Systems) reduced growth factor basement membrane matrix. The cells were treated with EBM-2 medium containing 2% serum from HIV+ patients obtained from NMH and UCSF wherever mentioned. Following a 20 hr incubation, tube networks from each biological replicate were analyzed in at least three random fields by light microscopy. The number of branch points (junctions), segments and meshes, and total length of tubule networks (total length of branching) was quantified by Fiji software (Angiogenesis Analyzer).</p></sec><sec id="s4-9"><title>Participant samples</title><p>Blood samples from six men with chronic HIV on ART with undetectable viral loads who underwent CMRI for the assessment of MPR were used. For CMRI, all scanning was performed on 1.5 T MRI scanners (Siemens Medical Systems), with participants receiving FDA-approved intravenous double-dosing of gadolinium contrast followed by adenosine as the vasodilator agent. Images were performed at maximal hyperemia (vasodilation) and compared with rest: MPR was calculated as the ratio of stress myocardial blood flow to rest myocardial blood flow as described previously (<xref ref-type="bibr" rid="bib32">Lee and Johnson, 2009</xref>). Comparisons in hiPSC-CM performance characteristics were made between those with higher (1.9–3.4; N = 3) versus lower (1.0–1.1; N = 3) MPR values; additional clinical and MRI-based characteristics are included in <xref ref-type="table" rid="table1">Table 1</xref>. The study was approved by the Institutional Review Board of Northwestern University (STU00204874).</p><p>Serum samples from UCSF are from an IRB-approved (IRB# 10-03112) longitudinal cohort study evaluating the pathogenesis of HIV and HHV-8 to pulmonary hypertension. PLWH underwent serial phlebotomy, transthoracic echocardiogram, flow-mediated dilation, 6 min walk test, and pulse wave velocity measurements. A subset of participants underwent a right heart catheterization. The study is IRB-approved, and participants provided signed informed consent prior to undergoing study procedures. Serum samples are derived from documented HIV-positive individuals on stable ART and have diastolic function assessed by echocardiogram. Samples are de-identified and stored long term with UCSF’s AIDS Specimen Bank (ASB).</p><p>Of the 16 participants included from UCSF, median age was 54.1 (IQR 45.0, 57.1), median duration of HIV infection was 17 years (IQR 12.7, 22.7), median CD4 count was 395 (IQR 334, 645), 88% were male, 50% were Caucasian, 37% were African American, and 13% were Hispanic/Latino. Comorbidities included 43.8% had hypertension, 31.3% had hyperlipidemia, 12.5% had diabetes, and 62.5% were current or past smokers. All specimens were matched case–control to those with DD to those without DD.</p><p>Baseline echocardiogram characteristics included everyone with preserved LV systolic function (≥50%). In the DD group, n = 2 had grade 1 DD, n = 3 had grade 2 DD, and n = 3 had grade 3 DD. Two individuals in the DD group had mild left atrial enlargement (LA volume index 35–41 ml/m<sup>2</sup>). Five individuals in the DD group and two in the control group had RVSP ≥ 35 mmHg.</p><p>Twelve participants (six from each group) underwent right heart catheterization with two in the DD group having elevated mean pulmonary arterial pressure (≥25 mmHg). Three participants in the DD group and two in the control group had right atrial pressure &gt;5 mmHg.</p></sec><sec id="s4-10"><title>Statistical analysis</title><p>Data are presented as mean ± SEM. Unpaired Student’s <italic>t</italic>-test and one-way ANOVA, with post hoc Tukey’s test were conducted to assess statistical significant difference among experimental groups. A p-value &lt;0.05 was considered statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>Reviewing editor, <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Software, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Formal analysis, Supervision, Investigation</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Formal analysis, Supervision, Investigation</p></fn><fn fn-type="con" id="con5"><p>Resources, Software, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con6"><p>Resources, Software, Investigation</p></fn><fn fn-type="con" id="con7"><p>Resources, Software, Supervision, Validation</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con10"><p>Resources</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Supervision, Funding acquisition, Validation, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Protocols and consents for the generation of hiPSCs and the differentiation into hiPSC-CMs were approved by the institutional review board (IRB) of Northwestern University (STU00204341). Cardiac MRI study and the serum collection from HIV patients were approved by the IRB of Northwestern University as well (STU00204874). Participants in UCSF whose serum and clinical physiological data were used for this study provided signed informed consent prior to undergoing study procedures, and the study is an IRB-approved cohort study in UCSF (IRB# 10-03112) .</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-95867-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files; source data files have been provided for Figures 1-6, Figure 1—figure supplement 1, Figure 3—figure supplement 1 and Figure 4—figure supplement 1.</p></sec><ack id="ack"><title>Acknowledgements</title><p>Funding for this work was provided through NHLBI HL140973 awarded to HA and the American Heart Association grant SP0065527 to YT. HA and YT conceptualized the project and wrote the paper. CC, JS, H-CC, MB, and DL-L, carried out the experiments. MF and PH provided human samples. PWB and RD provided scientific guidance.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amirayan-Chevillard</surname><given-names>N</given-names></name><name><surname>Tissot-Dupont</surname><given-names>H</given-names></name><name><surname>Capo</surname><given-names>C</given-names></name><name><surname>Brunet</surname><given-names>C</given-names></name><name><surname>Dignat-George</surname><given-names>F</given-names></name><name><surname>Obadia</surname><given-names>Y</given-names></name><name><surname>Gallais</surname><given-names>H</given-names></name><name><surname>Mege</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients</article-title><source>Clinical and Experimental Immunology</source><volume>120</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.2000.01201.x</pub-id><pub-id pub-id-type="pmid">10759771</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Ferreira</surname><given-names>JP</given-names></name><name><surname>Bocchi</surname><given-names>E</given-names></name><name><surname>Böhm</surname><given-names>M</given-names></name><name><surname>Brunner-La Rocca</surname><given-names>H-P</given-names></name><name><surname>Choi</surname><given-names>D-J</given-names></name><name><surname>Chopra</surname><given-names>V</given-names></name><name><surname>Chuquiure-Valenzuela</surname><given-names>E</given-names></name><name><surname>Giannetti</surname><given-names>N</given-names></name><name><surname>Gomez-Mesa</surname><given-names>JE</given-names></name><name><surname>Janssens</surname><given-names>S</given-names></name><name><surname>Januzzi</surname><given-names>JL</given-names></name><name><surname>Gonzalez-Juanatey</surname><given-names>JR</given-names></name><name><surname>Merkely</surname><given-names>B</given-names></name><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Perrone</surname><given-names>SV</given-names></name><name><surname>Piña</surname><given-names>IL</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Senni</surname><given-names>M</given-names></name><name><surname>Sim</surname><given-names>D</given-names></name><name><surname>Spinar</surname><given-names>J</given-names></name><name><surname>Squire</surname><given-names>I</given-names></name><name><surname>Taddei</surname><given-names>S</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Vinereanu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Carson</surname><given-names>P</given-names></name><name><surname>Lam</surname><given-names>CSP</given-names></name><name><surname>Marx</surname><given-names>N</given-names></name><name><surname>Zeller</surname><given-names>C</given-names></name><name><surname>Sattar</surname><given-names>N</given-names></name><name><surname>Jamal</surname><given-names>W</given-names></name><name><surname>Schnaidt</surname><given-names>S</given-names></name><name><surname>Schnee</surname><given-names>JM</given-names></name><name><surname>Brueckmann</surname><given-names>M</given-names></name><name><surname>Pocock</surname><given-names>SJ</given-names></name><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>Packer</surname><given-names>M</given-names></name><collab>EMPEROR-Preserved Trial Investigators</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Empagliflozin in heart failure with a preserved ejection fraction</article-title><source>The New England Journal of Medicine</source><volume>385</volume><fpage>1451</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2107038</pub-id><pub-id pub-id-type="pmid">34449189</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>JR</given-names></name><name><surname>Kanagala</surname><given-names>P</given-names></name><name><surname>Budgeon</surname><given-names>CA</given-names></name><name><surname>Jerosch-Herold</surname><given-names>M</given-names></name><name><surname>Gulsin</surname><given-names>GS</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>JN</given-names></name><name><surname>Chan</surname><given-names>DCS</given-names></name><name><surname>Squire</surname><given-names>IB</given-names></name><name><surname>Ng</surname><given-names>LL</given-names></name><name><surname>McCann</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Prevalence and prognostic significance of microvascular dysfunction in heart failure with preserved ejection fraction</article-title><source>JACC. Cardiovascular Imaging</source><volume>15</volume><fpage>1001</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2021.11.022</pub-id><pub-id pub-id-type="pmid">35033490</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahrami</surname><given-names>H</given-names></name><name><surname>Budoff</surname><given-names>M</given-names></name><name><surname>Haberlen</surname><given-names>SA</given-names></name><name><surname>Rezaeian</surname><given-names>P</given-names></name><name><surname>Ketlogetswe</surname><given-names>K</given-names></name><name><surname>Tracy</surname><given-names>R</given-names></name><name><surname>Palella</surname><given-names>F</given-names></name><name><surname>Witt</surname><given-names>MD</given-names></name><name><surname>McConnell</surname><given-names>MV</given-names></name><name><surname>Kingsley</surname><given-names>L</given-names></name><name><surname>Post</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inflammatory markers associated with subclinical coronary artery disease: The multicenter AIDS cohort study</article-title><source>Journal of the American Heart Association</source><volume>5</volume><elocation-id>e003371</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.116.003371</pub-id><pub-id pub-id-type="pmid">27353609</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bers</surname><given-names>DM</given-names></name><name><surname>Xiang</surname><given-names>YK</given-names></name><name><surname>Zaccolo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Whole-Cell cAMP and PKA Activity are epiphenomena, nanodomain signaling matters</article-title><source>Physiology</source><volume>34</volume><fpage>240</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1152/physiol.00002.2019</pub-id><pub-id pub-id-type="pmid">31165682</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berzingi</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Finkel</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>p38 MAP kinase inhibitor prevents diastolic dysfunction in rats following HIV gp120 injection in vivo</article-title><source>Cardiovascular Toxicology</source><volume>9</volume><fpage>142</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1007/s12012-009-9047-1</pub-id><pub-id pub-id-type="pmid">19644660</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burridge</surname><given-names>PW</given-names></name><name><surname>Holmström</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chemically defined culture and cardiomyocyte differentiation of human pluripotent stem cells</article-title><source>Current Protocols in Human Genetics</source><volume>87</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1002/0471142905.hg2103s87</pub-id><pub-id pub-id-type="pmid">26439715</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvajal-Vergara</surname><given-names>X</given-names></name><name><surname>Sevilla</surname><given-names>A</given-names></name><name><surname>D’Souza</surname><given-names>SL</given-names></name><name><surname>Ang</surname><given-names>Y-S</given-names></name><name><surname>Schaniel</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>D-F</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Kaplan</surname><given-names>AD</given-names></name><name><surname>Adler</surname><given-names>ED</given-names></name><name><surname>Rozov</surname><given-names>R</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><name><surname>Edelmann</surname><given-names>LJ</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Waghray</surname><given-names>A</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Pardo</surname><given-names>S</given-names></name><name><surname>Lichtenbelt</surname><given-names>KD</given-names></name><name><surname>Tartaglia</surname><given-names>M</given-names></name><name><surname>Gelb</surname><given-names>BD</given-names></name><name><surname>Lemischka</surname><given-names>IR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome</article-title><source>Nature</source><volume>465</volume><fpage>808</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/nature09005</pub-id><pub-id pub-id-type="pmid">20535210</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>LRV</given-names></name><name><surname>Verde</surname><given-names>I</given-names></name><name><surname>Cooper</surname><given-names>DMF</given-names></name><name><surname>Fischmeister</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes</article-title><source>Circulation</source><volume>113</volume><fpage>2221</fpage><lpage>2228</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.599241</pub-id><pub-id pub-id-type="pmid">16651469</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>JM</given-names></name><name><surname>Akkerhuis</surname><given-names>KM</given-names></name><name><surname>Battes</surname><given-names>LC</given-names></name><name><surname>van Vark</surname><given-names>LC</given-names></name><name><surname>Hillege</surname><given-names>HL</given-names></name><name><surname>Paulus</surname><given-names>WJ</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Kardys</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Biomarkers of heart failure with normal ejection fraction: a systematic review</article-title><source>European Journal of Heart Failure</source><volume>15</volume><fpage>1350</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hft106</pub-id><pub-id pub-id-type="pmid">23845797</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churko</surname><given-names>JM</given-names></name><name><surname>Burridge</surname><given-names>PW</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Generation of human iPSCs from human peripheral blood mononuclear cells using non-integrative Sendai virus in chemically defined conditions</article-title><source>Methods in Molecular Biology</source><volume>1036</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-511-8_7</pub-id><pub-id pub-id-type="pmid">23807788</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornuault</surname><given-names>L</given-names></name><name><surname>Rouault</surname><given-names>P</given-names></name><name><surname>Duplàa</surname><given-names>C</given-names></name><name><surname>Couffinhal</surname><given-names>T</given-names></name><name><surname>Renault</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Endothelial dysfunction in heart failure with preserved ejection fraction: What are the experimental proofs?</article-title><source>Frontiers in Physiology</source><volume>13</volume><elocation-id>906272</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2022.906272</pub-id><pub-id pub-id-type="pmid">35874523</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>GX</given-names></name><name><surname>Bonkowski</surname><given-names>MS</given-names></name><name><surname>Longchamp</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Impairment of an endothelial NAD(+)-H(2)S signaling network is a reversible cause of vascular aging</article-title><source>Cell</source><volume>173</volume><fpage>74</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.02.008</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhingra</surname><given-names>A</given-names></name><name><surname>Garg</surname><given-names>A</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name><name><surname>Chopra</surname><given-names>S</given-names></name><name><surname>Batra</surname><given-names>JS</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Chaanine</surname><given-names>AH</given-names></name><name><surname>Agarwal</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Epidemiology of heart failure with preserved ejection fraction</article-title><source>Current Heart Failure Reports</source><volume>11</volume><fpage>354</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1007/s11897-014-0223-7</pub-id><pub-id pub-id-type="pmid">25224319</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Droste</surname><given-names>JAH</given-names></name><name><surname>Verweij-van Wissen</surname><given-names>CPWGM</given-names></name><name><surname>Kearney</surname><given-names>BP</given-names></name><name><surname>Buffels</surname><given-names>R</given-names></name><name><surname>Vanhorssen</surname><given-names>PJ</given-names></name><name><surname>Hekster</surname><given-names>YA</given-names></name><name><surname>Burger</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>49</volume><fpage>680</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.2.680-684.2005</pub-id><pub-id pub-id-type="pmid">15673751</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fentzke</surname><given-names>RC</given-names></name><name><surname>Buck</surname><given-names>SH</given-names></name><name><surname>Patel</surname><given-names>JR</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Wolska</surname><given-names>BM</given-names></name><name><surname>Stojanovic</surname><given-names>MO</given-names></name><name><surname>Martin</surname><given-names>AF</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name><name><surname>Moss</surname><given-names>RL</given-names></name><name><surname>Leiden</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Impaired cardiomyocyte relaxation and diastolic function in transgenic mice expressing slow skeletal troponin I in the heart</article-title><source>The Journal of Physiology</source><volume>517 (Pt 1)</volume><fpage>143</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7793.1999.0143z.x</pub-id><pub-id pub-id-type="pmid">10226156</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feridooni</surname><given-names>HA</given-names></name><name><surname>Dibb</surname><given-names>KM</given-names></name><name><surname>Howlett</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>How cardiomyocyte excitation, calcium release and contraction become altered with age</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>83</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2014.12.004</pub-id><pub-id pub-id-type="pmid">25498213</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haass</surname><given-names>M</given-names></name><name><surname>Kitzman</surname><given-names>DW</given-names></name><name><surname>Anand</surname><given-names>IS</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Zile</surname><given-names>MR</given-names></name><name><surname>Massie</surname><given-names>BM</given-names></name><name><surname>Carson</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial</article-title><source>Circulation. Heart Failure</source><volume>4</volume><fpage>324</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.110.959890</pub-id><pub-id pub-id-type="pmid">21350053</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsue</surname><given-names>PY</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Ho</surname><given-names>JE</given-names></name><name><surname>Farah</surname><given-names>HH</given-names></name><name><surname>Schnell</surname><given-names>A</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Bolger</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Impact of HIV infection on diastolic function and left ventricular mass</article-title><source>Circulation. Heart Failure</source><volume>3</volume><fpage>132</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.109.854943</pub-id><pub-id pub-id-type="pmid">19933410</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itzhaki</surname><given-names>I</given-names></name><name><surname>Maizels</surname><given-names>L</given-names></name><name><surname>Huber</surname><given-names>I</given-names></name><name><surname>Zwi-Dantsis</surname><given-names>L</given-names></name><name><surname>Caspi</surname><given-names>O</given-names></name><name><surname>Winterstern</surname><given-names>A</given-names></name><name><surname>Feldman</surname><given-names>O</given-names></name><name><surname>Gepstein</surname><given-names>A</given-names></name><name><surname>Arbel</surname><given-names>G</given-names></name><name><surname>Hammerman</surname><given-names>H</given-names></name><name><surname>Boulos</surname><given-names>M</given-names></name><name><surname>Gepstein</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Modelling the long QT syndrome with induced pluripotent stem cells</article-title><source>Nature</source><volume>471</volume><fpage>225</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1038/nature09747</pub-id><pub-id pub-id-type="pmid">21240260</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakuda</surname><given-names>TN</given-names></name><name><surname>Brochot</surname><given-names>A</given-names></name><name><surname>Tomaka</surname><given-names>FL</given-names></name><name><surname>Vangeneugden</surname><given-names>T</given-names></name><name><surname>Van De Casteele</surname><given-names>T</given-names></name><name><surname>Hoetelmans</surname><given-names>RMW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>69</volume><fpage>2591</fpage><lpage>2605</lpage><pub-id pub-id-type="doi">10.1093/jac/dku193</pub-id><pub-id pub-id-type="pmid">24951533</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kan</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Finkel</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>p38 MAP kinase-mediated negative inotropic effect of HIV gp120 on cardiac myocytes</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>286</volume><fpage>C1</fpage><lpage>C7</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00059.2003</pub-id><pub-id pub-id-type="pmid">14660488</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kardys</surname><given-names>I</given-names></name><name><surname>Deckers</surname><given-names>JW</given-names></name><name><surname>Stricker</surname><given-names>BHC</given-names></name><name><surname>Vletter</surname><given-names>WB</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Witteman</surname><given-names>JCM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Echocardiographic parameters and all-cause mortality: the Rotterdam Study</article-title><source>International Journal of Cardiology</source><volume>133</volume><fpage>198</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2007.12.031</pub-id><pub-id pub-id-type="pmid">18313776</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsikis</surname><given-names>PD</given-names></name><name><surname>Mueller</surname><given-names>YM</given-names></name><name><surname>Villinger</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point?</article-title><source>PLOS Pathogens</source><volume>7</volume><elocation-id>e1002055</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002055</pub-id><pub-id pub-id-type="pmid">21852945</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keating</surname><given-names>SM</given-names></name><name><surname>Golub</surname><given-names>ET</given-names></name><name><surname>Nowicki</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>M</given-names></name><name><surname>Anastos</surname><given-names>K</given-names></name><name><surname>Crystal</surname><given-names>H</given-names></name><name><surname>Cohen</surname><given-names>MH</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Greenblatt</surname><given-names>RM</given-names></name><name><surname>Desai</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Landay</surname><given-names>AL</given-names></name><name><surname>Gange</surname><given-names>SJ</given-names></name><name><surname>Norris</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women</article-title><source>AIDS</source><volume>25</volume><fpage>1823</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e3283489d1f</pub-id><pub-id pub-id-type="pmid">21572306</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>KM</given-names></name><name><surname>Tocchetti</surname><given-names>CG</given-names></name><name><surname>Lyashkov</surname><given-names>A</given-names></name><name><surname>Tarwater</surname><given-names>PM</given-names></name><name><surname>Bedja</surname><given-names>D</given-names></name><name><surname>Graham</surname><given-names>DR</given-names></name><name><surname>Beck</surname><given-names>SE</given-names></name><name><surname>Metcalf Pate</surname><given-names>KA</given-names></name><name><surname>Queen</surname><given-names>SE</given-names></name><name><surname>Adams</surname><given-names>RJ</given-names></name><name><surname>Paolocci</surname><given-names>N</given-names></name><name><surname>Mankowski</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CCR5 inhibition prevents cardiac dysfunction in the SIV/macaque model of HIV</article-title><source>Journal of the American Heart Association</source><volume>3</volume><elocation-id>e000874</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.114.000874</pub-id><pub-id pub-id-type="pmid">24695652</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiso</surname><given-names>H</given-names></name><name><surname>Ohba</surname><given-names>T</given-names></name><name><surname>Iino</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Terata</surname><given-names>Y</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sildenafil prevents the up-regulation of transient receptor potential canonical channels in the development of cardiomyocyte hypertrophy</article-title><source>Biochemical and Biophysical Research Communications</source><volume>436</volume><fpage>514</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2013.06.002</pub-id><pub-id pub-id-type="pmid">23764398</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosiborod</surname><given-names>MN</given-names></name><name><surname>Abildstrøm</surname><given-names>SZ</given-names></name><name><surname>Borlaug</surname><given-names>BA</given-names></name><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Rasmussen</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Hovingh</surname><given-names>GK</given-names></name><name><surname>Kitzman</surname><given-names>DW</given-names></name><name><surname>Lindegaard</surname><given-names>ML</given-names></name><name><surname>Møller</surname><given-names>DV</given-names></name><name><surname>Shah</surname><given-names>SJ</given-names></name><name><surname>Treppendahl</surname><given-names>MB</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Abhayaratna</surname><given-names>W</given-names></name><name><surname>Ahmed</surname><given-names>FZ</given-names></name><name><surname>Chopra</surname><given-names>V</given-names></name><name><surname>Ezekowitz</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Lelonek</surname><given-names>M</given-names></name><name><surname>Melenovsky</surname><given-names>V</given-names></name><name><surname>Merkely</surname><given-names>B</given-names></name><name><surname>Núñez</surname><given-names>J</given-names></name><name><surname>Perna</surname><given-names>E</given-names></name><name><surname>Schou</surname><given-names>M</given-names></name><name><surname>Senni</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Van der Meer</surname><given-names>P</given-names></name><name><surname>von Lewinski</surname><given-names>D</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Petrie</surname><given-names>MC</given-names></name><collab>STEP-HFpEF Trial Committees and Investigators</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Semaglutide in patients with heart failure with preserved ejection fraction and obesity</article-title><source>The New England Journal of Medicine</source><volume>389</volume><fpage>1069</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2306963</pub-id><pub-id pub-id-type="pmid">37622681</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>AA</given-names></name><name><surname>Kelly</surname><given-names>DP</given-names></name><name><surname>Chirinos</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mitochondrial dysfunction in heart failure with preserved ejection fraction</article-title><source>Circulation</source><volume>139</volume><fpage>1435</fpage><lpage>1450</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.036259</pub-id><pub-id pub-id-type="pmid">30856000</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>AS</given-names></name><name><surname>Liang</surname><given-names>P</given-names></name><name><surname>Sanchez-Freire</surname><given-names>V</given-names></name><name><surname>Nguyen</surname><given-names>PK</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Yen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>N</given-names></name><name><surname>Abilez</surname><given-names>OJ</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>AD</given-names></name><name><surname>Navarrete</surname><given-names>EG</given-names></name><name><surname>Simmons</surname><given-names>CS</given-names></name><name><surname>Wheeler</surname><given-names>M</given-names></name><name><surname>Pruitt</surname><given-names>B</given-names></name><name><surname>Lewis</surname><given-names>R</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Bers</surname><given-names>DM</given-names></name><name><surname>Robbins</surname><given-names>RC</given-names></name><name><surname>Longaker</surname><given-names>MT</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells</article-title><source>Cell Stem Cell</source><volume>12</volume><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.10.010</pub-id><pub-id pub-id-type="pmid">23290139</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S-H</given-names></name><name><surname>Chen</surname><given-names>Y-C</given-names></name><name><surname>Chen</surname><given-names>Y-J</given-names></name><name><surname>Chang</surname><given-names>S-L</given-names></name><name><surname>Tai</surname><given-names>C-T</given-names></name><name><surname>Wongcharoen</surname><given-names>W</given-names></name><name><surname>Yeh</surname><given-names>H-I</given-names></name><name><surname>Lin</surname><given-names>C-I</given-names></name><name><surname>Chen</surname><given-names>S-A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes</article-title><source>Life Sciences</source><volume>80</volume><fpage>1806</fpage><lpage>1815</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2007.02.029</pub-id><pub-id pub-id-type="pmid">17383682</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DC</given-names></name><name><surname>Johnson</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Quantification of absolute myocardial blood flow by magnetic resonance perfusion imaging</article-title><source>JACC</source><volume>2</volume><fpage>761</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2009.04.003</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DI</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>G-S</given-names></name><name><surname>Hamdani</surname><given-names>N</given-names></name><name><surname>Holewinski</surname><given-names>R</given-names></name><name><surname>Jo</surname><given-names>S-H</given-names></name><name><surname>Danner</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Rainer</surname><given-names>PP</given-names></name><name><surname>Bedja</surname><given-names>D</given-names></name><name><surname>Kirk</surname><given-names>JA</given-names></name><name><surname>Ranek</surname><given-names>MJ</given-names></name><name><surname>Dostmann</surname><given-names>WR</given-names></name><name><surname>Kwon</surname><given-names>C</given-names></name><name><surname>Margulies</surname><given-names>KB</given-names></name><name><surname>Van Eyk</surname><given-names>JE</given-names></name><name><surname>Paulus</surname><given-names>WJ</given-names></name><name><surname>Takimoto</surname><given-names>E</given-names></name><name><surname>Kass</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease</article-title><source>Nature</source><volume>519</volume><fpage>472</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/nature14332</pub-id><pub-id pub-id-type="pmid">25799991</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>P</given-names></name><name><surname>Lan</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>AS</given-names></name><name><surname>Gong</surname><given-names>T</given-names></name><name><surname>Sanchez-Freire</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Diecke</surname><given-names>S</given-names></name><name><surname>Sallam</surname><given-names>K</given-names></name><name><surname>Knowles</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>PJ</given-names></name><name><surname>Nguyen</surname><given-names>PK</given-names></name><name><surname>Bers</surname><given-names>DM</given-names></name><name><surname>Robbins</surname><given-names>RC</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity</article-title><source>Circulation</source><volume>127</volume><fpage>1677</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.001883</pub-id><pub-id pub-id-type="pmid">23519760</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyra-Leite</surname><given-names>DM</given-names></name><name><surname>Copley</surname><given-names>RR</given-names></name><name><surname>Freeman</surname><given-names>PP</given-names></name><name><surname>Pongpamorn</surname><given-names>P</given-names></name><name><surname>Shah</surname><given-names>D</given-names></name><name><surname>McKenna</surname><given-names>DE</given-names></name><name><surname>Lenny</surname><given-names>B</given-names></name><name><surname>Pinheiro</surname><given-names>EA</given-names></name><name><surname>Weddle</surname><given-names>CJ</given-names></name><name><surname>Gharib</surname><given-names>M</given-names></name><name><surname>Javed</surname><given-names>H</given-names></name><name><surname>Fonoudi</surname><given-names>H</given-names></name><name><surname>Sapkota</surname><given-names>Y</given-names></name><name><surname>Burridge</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Nutritional requirements of human induced pluripotent stem cells</article-title><source>Stem Cell Reports</source><volume>18</volume><fpage>1371</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2023.05.004</pub-id><pub-id pub-id-type="pmid">37315525</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marfella</surname><given-names>R</given-names></name><name><surname>Scisciola</surname><given-names>L</given-names></name><name><surname>D’Onofrio</surname><given-names>N</given-names></name><name><surname>Maiello</surname><given-names>C</given-names></name><name><surname>Trotta</surname><given-names>MC</given-names></name><name><surname>Sardu</surname><given-names>C</given-names></name><name><surname>Panarese</surname><given-names>I</given-names></name><name><surname>Ferraraccio</surname><given-names>F</given-names></name><name><surname>Capuano</surname><given-names>A</given-names></name><name><surname>Barbieri</surname><given-names>M</given-names></name><name><surname>Balestrieri</surname><given-names>ML</given-names></name><name><surname>Napoli</surname><given-names>C</given-names></name><name><surname>Paolisso</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes</article-title><source>Pharmacological Research</source><volume>184</volume><elocation-id>106448</elocation-id><pub-id pub-id-type="doi">10.1016/j.phrs.2022.106448</pub-id><pub-id pub-id-type="pmid">36096423</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markley</surname><given-names>R</given-names></name><name><surname>Del Buono</surname><given-names>MG</given-names></name><name><surname>Mihalick</surname><given-names>V</given-names></name><name><surname>Pandelidis</surname><given-names>A</given-names></name><name><surname>Trankle</surname><given-names>C</given-names></name><name><surname>Jordan</surname><given-names>JH</given-names></name><name><surname>Decamp</surname><given-names>K</given-names></name><name><surname>Winston</surname><given-names>C</given-names></name><name><surname>Carbone</surname><given-names>S</given-names></name><name><surname>Billingsley</surname><given-names>H</given-names></name><name><surname>Barron</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Van Tassell</surname><given-names>B</given-names></name><name><surname>Hundley</surname><given-names>WG</given-names></name><name><surname>Kellman</surname><given-names>P</given-names></name><name><surname>Abbate</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Abnormal left ventricular subendocardial perfusion and diastolic function in women with obesity and heart failure and preserved ejection fraction</article-title><source>The International Journal of Cardiovascular Imaging</source><volume>39</volume><fpage>811</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1007/s10554-022-02782-x</pub-id><pub-id pub-id-type="pmid">36607469</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Lima</surname><given-names>JAC</given-names></name><name><surname>Lai</surname><given-names>H</given-names></name><name><surname>Vlahov</surname><given-names>D</given-names></name><name><surname>Celentano</surname><given-names>DD</given-names></name><name><surname>Strathdee</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>KE</given-names></name><name><surname>Tong</surname><given-names>W</given-names></name><name><surname>Lai</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction</article-title><source>Journal of Acquired Immune Deficiency Syndromes</source><volume>30</volume><fpage>306</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1097/00126334-200207010-00006</pub-id><pub-id pub-id-type="pmid">12131567</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musa</surname><given-names>F</given-names></name><name><surname>Shaviya</surname><given-names>N</given-names></name><name><surname>Mambo</surname><given-names>F</given-names></name><name><surname>Abonyo</surname><given-names>C</given-names></name><name><surname>Barasa</surname><given-names>E</given-names></name><name><surname>Wafula</surname><given-names>P</given-names></name><name><surname>Sowayi</surname><given-names>G</given-names></name><name><surname>Barasa</surname><given-names>M</given-names></name><name><surname>Were</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cytokine profiles in highly active antiretroviral treatment non-adherent, adherent and naive HIV-1 infected patients in Western Kenya</article-title><source>African Health Sciences</source><volume>21</volume><fpage>1584</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.4314/ahs.v21i4.12</pub-id><pub-id pub-id-type="pmid">35283948</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarrete</surname><given-names>EG</given-names></name><name><surname>Liang</surname><given-names>P</given-names></name><name><surname>Lan</surname><given-names>F</given-names></name><name><surname>Sanchez-Freire</surname><given-names>V</given-names></name><name><surname>Simmons</surname><given-names>C</given-names></name><name><surname>Gong</surname><given-names>T</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Burridge</surname><given-names>PW</given-names></name><name><surname>Patlolla</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>AS</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Beygui</surname><given-names>RE</given-names></name><name><surname>Wu</surname><given-names>SM</given-names></name><name><surname>Robbins</surname><given-names>RC</given-names></name><name><surname>Bers</surname><given-names>DM</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays</article-title><source>Circulation</source><volume>128</volume><fpage>S3</fpage><lpage>S13</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.000570</pub-id><pub-id pub-id-type="pmid">24030418</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osuji</surname><given-names>FN</given-names></name><name><surname>Onyenekwe</surname><given-names>CC</given-names></name><name><surname>Ahaneku</surname><given-names>JE</given-names></name><name><surname>Ukibe</surname><given-names>NR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The effects of highly active antiretroviral therapy on the serum levels of pro-inflammatory and anti-inflammatory cytokines in HIV infected subjects</article-title><source>Journal of Biomedical Science</source><volume>25</volume><elocation-id>88</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-018-0490-9</pub-id><pub-id pub-id-type="pmid">30501642</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulus</surname><given-names>WJ</given-names></name><name><surname>Tschöpe</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation</article-title><source>Journal of the American College of Cardiology</source><volume>62</volume><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.02.092</pub-id><pub-id pub-id-type="pmid">23684677</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Treatment of heart failure with preserved ejection fraction: Reflections on its treatment with an aldosterone antagonist</article-title><source>JAMA Cardiology</source><volume>1</volume><fpage>7</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2015.0356</pub-id><pub-id pub-id-type="pmid">27437645</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>LA</given-names></name><name><surname>Arango</surname><given-names>TA</given-names></name><name><surname>Thompson</surname><given-names>E</given-names></name><name><surname>Naji</surname><given-names>M</given-names></name><name><surname>Tebas</surname><given-names>P</given-names></name><name><surname>Boyer</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART</article-title><source>Journal of Leukocyte Biology</source><volume>96</volume><fpage>1055</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1189/jlb.3A0414-232RR</pub-id><pub-id pub-id-type="pmid">25157027</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinke</surname><given-names>Y</given-names></name><name><surname>Gross</surname><given-names>S</given-names></name><name><surname>Eckerle</surname><given-names>LG</given-names></name><name><surname>Hertrich</surname><given-names>I</given-names></name><name><surname>Busch</surname><given-names>M</given-names></name><name><surname>Busch</surname><given-names>R</given-names></name><name><surname>Riad</surname><given-names>A</given-names></name><name><surname>Rauch</surname><given-names>BH</given-names></name><name><surname>Stasch</surname><given-names>J-P</given-names></name><name><surname>Dörr</surname><given-names>M</given-names></name><name><surname>Felix</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats</article-title><source>European Journal of Pharmacology</source><volume>767</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.09.022</pub-id><pub-id pub-id-type="pmid">26407652</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roff</surname><given-names>SR</given-names></name><name><surname>Noon-Song</surname><given-names>EN</given-names></name><name><surname>Yamamoto</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The significance of interferon-γ in HIV-1 pathogenesis, therapy, and prophylaxis</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>498</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00498</pub-id><pub-id pub-id-type="pmid">24454311</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero-Tejeda</surname><given-names>M</given-names></name><name><surname>Fonoudi</surname><given-names>H</given-names></name><name><surname>Weddle</surname><given-names>CJ</given-names></name><name><surname>DeKeyser</surname><given-names>J-M</given-names></name><name><surname>Lenny</surname><given-names>B</given-names></name><name><surname>Fetterman</surname><given-names>KA</given-names></name><name><surname>Magdy</surname><given-names>T</given-names></name><name><surname>Sapkota</surname><given-names>Y</given-names></name><name><surname>Epting</surname><given-names>CL</given-names></name><name><surname>Burridge</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A novel transcription factor combination for direct reprogramming to A spontaneously contracting human cardiomyocyte-like state</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>182</volume><fpage>30</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2023.06.005</pub-id><pub-id pub-id-type="pmid">37421991</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders-van Wijk</surname><given-names>S</given-names></name><name><surname>van Empel</surname><given-names>V</given-names></name><name><surname>Davarzani</surname><given-names>N</given-names></name><name><surname>Maeder</surname><given-names>MT</given-names></name><name><surname>Handschin</surname><given-names>R</given-names></name><name><surname>Pfisterer</surname><given-names>ME</given-names></name><name><surname>Brunner-La Rocca</surname><given-names>H-P</given-names></name><collab>TIME-CHF investigators</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction</article-title><source>European Journal of Heart Failure</source><volume>17</volume><fpage>1006</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1002/ejhf.414</pub-id><pub-id pub-id-type="pmid">26472682</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santhanakrishnan</surname><given-names>R</given-names></name><name><surname>Chong</surname><given-names>JPC</given-names></name><name><surname>Ng</surname><given-names>TP</given-names></name><name><surname>Ling</surname><given-names>LH</given-names></name><name><surname>Sim</surname><given-names>D</given-names></name><name><surname>Leong</surname><given-names>KTG</given-names></name><name><surname>Yeo</surname><given-names>PSD</given-names></name><name><surname>Ong</surname><given-names>HY</given-names></name><name><surname>Jaufeerally</surname><given-names>F</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Chai</surname><given-names>P</given-names></name><name><surname>Low</surname><given-names>AF</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Lam</surname><given-names>CSP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction</article-title><source>European Journal of Heart Failure</source><volume>14</volume><fpage>1338</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hfs130</pub-id><pub-id pub-id-type="pmid">22869458</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>I</given-names></name><name><surname>Thöni</surname><given-names>GJ</given-names></name><name><surname>Edérhy</surname><given-names>S</given-names></name><name><surname>Walther</surname><given-names>G</given-names></name><name><surname>Nottin</surname><given-names>S</given-names></name><name><surname>Vinet</surname><given-names>A</given-names></name><name><surname>Boccara</surname><given-names>F</given-names></name><name><surname>Khireddine</surname><given-names>M</given-names></name><name><surname>Girard</surname><given-names>P-M</given-names></name><name><surname>Mauboussin</surname><given-names>J-M</given-names></name><name><surname>Rouanet</surname><given-names>I</given-names></name><name><surname>Dauzat</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>A</given-names></name><name><surname>Messner-Pellenc</surname><given-names>P</given-names></name><name><surname>Obert</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy</article-title><source>The American Journal of Cardiology</source><volume>101</volume><fpage>1213</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2007.11.073</pub-id><pub-id pub-id-type="pmid">18394461</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Marceau</surname><given-names>C</given-names></name><name><surname>Hamaguchi</surname><given-names>R</given-names></name><name><surname>Burridge</surname><given-names>PW</given-names></name><name><surname>Rajarajan</surname><given-names>K</given-names></name><name><surname>Churko</surname><given-names>JM</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Sallam</surname><given-names>KI</given-names></name><name><surname>Matsa</surname><given-names>E</given-names></name><name><surname>Sturzu</surname><given-names>AC</given-names></name><name><surname>Che</surname><given-names>Y</given-names></name><name><surname>Ebert</surname><given-names>A</given-names></name><name><surname>Diecke</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>P</given-names></name><name><surname>Red-Horse</surname><given-names>K</given-names></name><name><surname>Carette</surname><given-names>JE</given-names></name><name><surname>Wu</surname><given-names>SM</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform</article-title><source>Circulation Research</source><volume>115</volume><fpage>556</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.303810</pub-id><pub-id pub-id-type="pmid">25015077</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiomi</surname><given-names>M</given-names></name><name><surname>Matsuki</surname><given-names>S</given-names></name><name><surname>Ikeda</surname><given-names>A</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Nishino</surname><given-names>N</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Irie</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study</article-title><source>Clinical Pharmacology in Drug Development</source><volume>4</volume><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1002/cpdd.164</pub-id><pub-id pub-id-type="pmid">27140802</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>N</given-names></name><name><surname>Yazawa</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Sanchez-Freire</surname><given-names>V</given-names></name><name><surname>Abilez</surname><given-names>OJ</given-names></name><name><surname>Navarrete</surname><given-names>EG</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Pavlovic</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Hajjar</surname><given-names>RJ</given-names></name><name><surname>Snyder</surname><given-names>MP</given-names></name><name><surname>Dolmetsch</surname><given-names>RE</given-names></name><name><surname>Butte</surname><given-names>MJ</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Longaker</surname><given-names>MT</given-names></name><name><surname>Robbins</surname><given-names>RC</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy</article-title><source>Science Translational Medicine</source><volume>4</volume><elocation-id>130ra47</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3003552</pub-id><pub-id pub-id-type="pmid">22517884</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>NI</given-names></name><name><surname>Bream</surname><given-names>JH</given-names></name><name><surname>Martínez-Maza</surname><given-names>O</given-names></name><name><surname>Macatangay</surname><given-names>B</given-names></name><name><surname>Galvin</surname><given-names>SR</given-names></name><name><surname>Margolick</surname><given-names>JB</given-names></name><name><surname>Jacobson</surname><given-names>LP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inflammatory biomarkers and mortality risk among HIV-Suppressed men: a multisite prospective cohort study</article-title><source>Clinical Infectious Diseases</source><volume>63</volume><fpage>984</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw409</pub-id><pub-id pub-id-type="pmid">27343547</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Soon</surname><given-names>GH</given-names></name><name><surname>Seng</surname><given-names>K-Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Yong</surname><given-names>E-L</given-names></name><name><surname>Goh</surname><given-names>B-C</given-names></name><name><surname>Flexner</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>55</volume><fpage>4090</fpage><lpage>4095</lpage><pub-id pub-id-type="doi">10.1128/AAC.00593-11</pub-id><pub-id pub-id-type="pmid">21746959</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>D</given-names></name><name><surname>Uehira</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>E</given-names></name><name><surname>Ueji</surname><given-names>T</given-names></name><name><surname>Hirota</surname><given-names>K</given-names></name><name><surname>Minami</surname><given-names>R</given-names></name><name><surname>Takahama</surname><given-names>S</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Sawamura</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Shirasaka</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Clinical characteristics of HIV-1-infected patients with high levels of plasma interferon-γ: a multicenter observational study</article-title><source>BMC Infectious Diseases</source><volume>19</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-018-3643-2</pub-id><pub-id pub-id-type="pmid">30611204</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Daimon</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cardiac aging phenomenon and its clinical features by echocardiography</article-title><source>Journal of Echocardiography</source><volume>14</volume><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1007/s12574-016-0292-6</pub-id><pub-id pub-id-type="pmid">27169598</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yazawa</surname><given-names>M</given-names></name><name><surname>Hsueh</surname><given-names>B</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>Pasca</surname><given-names>AM</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Hallmayer</surname><given-names>J</given-names></name><name><surname>Dolmetsch</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome</article-title><source>Nature</source><volume>471</volume><fpage>230</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1038/nature09855</pub-id><pub-id pub-id-type="pmid">21307850</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Kan</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Finkel</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>CXCR4 receptor antagonist blocks cardiac myocyte p38 MAP kinase phosphorylation by HIV gp120</article-title><source>Cardiovascular Toxicology</source><volume>8</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1007/s12012-008-9026-y</pub-id><pub-id pub-id-type="pmid">18850076</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>R</given-names></name><name><surname>Scholz</surname><given-names>PM</given-names></name><name><surname>Weiss</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Functional interaction of a beta-adrenergic agonist and cyclic GMP phosphodiesterase inhibitor in control and hypertrophic cardiomyocytes</article-title><source>Pharmacology</source><volume>76</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1159/000089550</pub-id><pub-id pub-id-type="pmid">16276122</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95867.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mani</surname><given-names>Arya</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Yale University School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Incomplete</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Useful</kwd></kwd-group></front-stub><body><p>This <bold>useful</bold> study focuses on heart failure with preserved ejection fraction (HFpFE), common in patients with HIV. Researchers used induced human pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to stimulate (HEFpEF) and found that inflammatory cytokines alter Ca2+ transients. SGLT2 inhibitors and mitochondrial antioxidants reversed this effect. While the study is <bold>incomplete</bold> and preliminary, its strength lies in introducing hiPSC-CMs as a tool for investigating HFpEF mechanisms. A major weakness was found to be limited functional assessment relevant to HFpEF.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95867.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This is a reviewed manuscript submission to better understand mechanisms for why HIV individuals have diastolic dysfunction. Due to a lack of robust animal models, the team developed iPS-CM models to study HFpEF. The revised manuscript has toned down claims regarding diastolic function given the lack of mechanical testing. The team has focused on the altered Ca2+ phenotype, which improves the precision of the claims of the team. There remain questions on the functional relevance of the altered calcium handling given the lack of physiological assays. There also remain some questions about whether SGLT2 protein is expressed in these models without testing it, and whether the effects of SGLT2i could be off-target.</p><p>Overall, the revised manuscript is improved. I have no major remaining concerns except that the lack of biomechanical assessments diminishes the significance of the study as altered calcium alone would not be considered sufficient evidence for diastolic dysfunction, which was major task set out to answer by the group.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95867.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The authors investigated the role of inflammatory molecules in diastolic dysfunction and screened antiviral and cardioprotective pharmacological agents for their potential to reverse inflammation-mediated diastolic dysfunction. This study focuses on heart failure with preserved ejection fraction (HFpEF) in people living with HIV (PLWH), a condition often challenging to study due to the lack of suitable animal models. Using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), researchers simulated HFpEF in vitro. They observed that inflammatory cytokines impaired cardiomyocyte relaxation, mimicking HFpEF, while SGLT2 inhibitors and mitochondrial antioxidants reversed this effect. Exposure to serum from HIV patients did not induce dysfunction in hiPSC-CMs. These findings suggest hiPSC-CMs as a promising model for understanding HFpEF mechanisms and testing potential treatments.</p><p>Comments on revised version:</p><p>The revised manuscript has been improved satisfactorily. The authors also have addressed all of my concerns.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95867.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ardehali</surname><given-names>Hossein</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Tatekoshi</surname><given-names>Yuki</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Chunlei</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Shapiro</surname><given-names>Jason Solomon</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Hsiang-Chun</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Blancard</surname><given-names>Malorie</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lyra-Leite</surname><given-names>Davi M</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Burridge</surname><given-names>Paul W</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Feinstein</surname><given-names>Matthew</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>D'Aquila</surname><given-names>Richard</given-names></name><role specific-use="author">Author</role><aff><institution>Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Hsue</surname><given-names>Priscilla</given-names></name><role specific-use="author">Author</role><aff><institution>UCSF</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>I am not convinced how this study relates to HIV individual HFpEF, and the study design does not seem to be well thought out.</p></disp-quote><p>This is an important point and we have modified the manuscript as mentioned below in our responses.</p><disp-quote content-type="editor-comment"><p>The connectivity of the study experiments is loose, and data analysis and conclusions are broadly overstated and misinterpreted.</p></disp-quote><p>We have modified the manuscript thoroughly so the data are interpret properly, and the conclusions are stated logically.</p><disp-quote content-type="editor-comment"><p>For example the study lacks any measure of diastolic contractile function, and even if performed, the relevance of TNFa treatments to cells in vitro in these immature cell contexts would remain unclear. There is surprisingly no reported molecular analyses of potential mechanisms of the calcium transient changes. The study falls short in molecular detail and instead relies on drug treatments and responses that are hard to interpret with dosages that are not well justified and treatments that are numerous. Unclear what changes in calcium transients mean functionally without a comprehensive assessment of CM biomechanical contraction and relaxation measurements, and this would also require parallel molecular investigations of potential targets of any phenotypes observed.</p></disp-quote><p>As mentioned above, we have modified the manuscript so the data are interpret properly, and the conclusions are stated logically. In terms of mechanisms for the observed phenomenon, we agree that this was not the focus of studies, however, we have provided a paragraph in the discussion that covers this topic. Although Decay and downstroke time were utilized as surrogates of cardiomyocyte relaxation, direct biomechanical characterization of contraction was not conducted in this study. While cytosolic calcium concentration is a predominant factor to regulate the cell’s relaxation (Reference 52 in the manuscript), there are several mechanisms to modify the relationship, including the transition of sarcomere protein isoforms to pathogenic ones (Reference 53 in the manuscript) and the stimulation of β-adrenergic receptor on cardiomyocytes (Reference 54 in the manuscript). Since hiPSC-CMs utilized for each study is from iPS cells derived from a single donor, we believe that the patterns of sarcomere protein expression and the regulation of β-adrenergic receptor pathway should be consistent among samples, supporting their effects should be minimum in our system. We also did not elucidate molecular mechanisms underlying prolonged decay time induced by TNF-α and IFN-γ in this study. Lee et al. reported that 25 ng/ml TNFa treatment induced a longer decay portion of the calcium transient and a decreased sarcoplasmic ATPase (SERCA) expression in rabbit cardiomyocytes from pulmonary vein (Reference 55 in the manuscript), suggesting our observation in iPS-CM is also through decreased expression of SERCA though further studies remain conducted.</p><disp-quote content-type="editor-comment"><p>Calcium transient data need to be better illustrated such as with representative peak tracings. The data overall is with too few samples, particularly given the inherent heterogeneity of iPSCM studies. The iPS-CM system as a model for diastolic dysfunction remains unestablished.</p></disp-quote><p>We have now prepared several representative curves of calcium transient and their derivatives in Figure 4 D and E, H and I, and in Figure 1-figure supplement 1B. In terms of the way to collect Ca-transient data, each dot in the bar graphs represents the average of signals obtained from one well of the 96-well plates. About 75K cells were seeded in one well, and we believe that the number of cells integrated in the analyses should be sufficient for the statistical analyses. We modified our manuscript as this system does not quantifying diastolic function directly, but represents Ca measurements that indicate cardiomyocyte relaxation.</p><disp-quote content-type="editor-comment"><p>There are unclear dose choices for the various ART drugs tested, as well as the other drugs tested such as SGLT2i. Besides the observation that SLC5A2 (SGLT2 target) is not established to be expressed in adult mammalian cardiomyocytes.</p></disp-quote><p>Thank you for the comment. The dose ranges of ART drugs were chosen to extend to 10fold above the IC50 concentrations and reflects the upper range of circulating drug concentration in patients receiving these medications (Reference 36-39 in the manuscript). For SGLT2 inhibitor concentration, we referred to a paper utilizing 1-10 μM dapagliflozin (PMID: 35818731). We conducted a preliminary study to test the effect of 1 and 10 μM of dapagliflozin on the Ca-transient of iPS-CMs, and we found that 1 μM of the drug treatment did not cause changes in Ca-transient. Marfella et al. reported that SLC5A2 (SGLT2) expresses in cardiomyocytes under diabetic condition (PMID 36096423). Since diabetes is associated with low grade systemic inflammation, HIV patients might also express SGLT2 in cardiomyocytes. Taken together, we believe that the dosages of the drugs used in our studies are relevant to the clinical therapeutical usages of the drugs.</p><disp-quote content-type="editor-comment"><p>HIV plasma samples were not tested for cytokine levels, but this could be done to assess the validity of the final experiments. It is unclear what is being tested with these experiments.</p></disp-quote><p>This is a good point and we agree with the reviewer. However, we had limited amount of the patient serum and could not perform a comprehensive analysis of these samples. Nevertheless, we have added a section in the Discussion section providing some clinical relevance of our findings based on the papers that have assessed cytokine levels in the serum of HIV patients.</p><disp-quote content-type="editor-comment"><p>The choice of serum controls from a second institution (UCSF) opens up concerns over batch effects unrelated to differences in diastolic dysfunction. However, there were no differences with the Northwestern samples. It is unclear why this data is included as it does not add to the impact of the study.</p></disp-quote><p>In our study, we utilized two sets of HIV patient serum samples from different institutions, supporting that our results can be reproduced. We believe that these results significantly augmented the rigor of our findings.</p><disp-quote content-type="editor-comment"><p>There are concerns about the quality of the iPS-CMs since there is no cell imaging or molecular analyses. Figure 5 Supplement 1 images are of low quality and low resolution to assess cell quality. Overall the iPS-CM QC data is extremely sparse</p></disp-quote><p>We have now added the representative images of iPS-CMs to Figure 1- figure supplement 1A. Our group has used hiPS-CMs extensively in the past (PMID: 26439715). We also updated Fig 5 Supplement 1 with images with better resolution and added Fig 5 Supplement 2 with magnified images.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer2 (Public Review):</bold></p><p>However, there are some topics that are not well-connected, and the rationale and hypothesis are not clearly defined beforehand, such as mitochondrial membrane potential, mitochondrial ROS, and angiogenic potential.</p></disp-quote><p>We modified the manuscript so the rationale and hypothesis of the study is clearly stated.</p><disp-quote content-type="editor-comment"><p>As the hiPSC cardiomyocytes are treated with various reagents to measure diastolic dysfunction, it is important to confirm whether the treatment time and dose used were sufficient to exert a functional effect. Dose and time-dependent experiments are essential, or at least sufficient citations should be provided for selecting the dose for IFN and TNF.</p></disp-quote><p>We used previous publications for the dosages of the drugs used in our paper (1-4).</p><disp-quote content-type="editor-comment"><p>After IFN and TNF treatment, determining the expression levels of molecular markers of DD/HFpEF is crucial. Again, if sufficient evidence is available, it can be cited.</p></disp-quote><p>We have included a section in the discussion to address this issue. Briefly, Lee et al. reported that 25 ng/ml TNFa induces a longer decay of calcium transient and a decrease in sarcoplasmic ATPase (SERCA) expression in rabbit cardiomyocytes from pulmonary vein (PMID 17383682). The prolonged Cadecay time in hiPS-CM with the drug administration may be due to a decrease in SERCA expression and impaired Ca-uptake into sarcoplasmic reticulum.</p><disp-quote content-type="editor-comment"><p>The Methods section describes TMRE colocalization and immunofluorescence, but no images are provided.</p></disp-quote><p>We have performed immunofluorescence of hiPSC-CM with TMRE for the quantification of mitochondrial membrane potential (MMP).</p><disp-quote content-type="editor-comment"><p>The concentration of TNF and IFN in patients is critical, which was acknowledged and discussed as a limitation of the study by the authors. Authors should consider this aspect, and if not feasible, clinical reports should be cited to provide a rough estimation of their concentration.</p></disp-quote><p>Thank you for this comment. A new section detailing the points brought up by the Reviewer is now added to discussion.</p><disp-quote content-type="editor-comment"><p><bold>Recommendation for the authors</bold>:</p><p><bold>Reviewer #1 (Recommendation for the authors):</bold></p><p>I suggest a more comprehensive analysis of diastolic function including biomechanical studies of contraction and diastolic function. I suggest increasing the sample #'s, getting a better characterziation of the cardiomyocytes, their expression profiles, and maturation state. The team should dig more deeply into potential molecular mechanisms of the calcium transient changes. Are there changes in SERCA or other SR factors' phosphorylation state or other molecular explanations for the observed changes? I would remove the serum treatment experiments as they distract since they didn't show differences. These are a few of the suggestions I would have for the team.</p></disp-quote><p>Our system for measurement of Ca-transient unfortunately does not allow to obtain data on the cellular biomechanical property. We modified the manuscript so the results are not overstated and that the interpretation is correct. Since each dot in bar-graphs for Ca-transient data represents the average of signals generated from 75 K cells, we believe that the number of cells analyzed was sufficient for the analyses. Although it is not conclusive, previous reports suggested induction of SERCA2A expression by TNF-α treatment in isolated cardiomyocytes, suggesting that the mechanism underlying the prolonged calcium decay time in our model may be due to changes in SERCA levels. We included the data from human serum samples from HIV patients since they provide a platform to assess the effects of HIV patient serum on. We believe that these data convey a significant progress understanding the process of myocardial dysfunction in HIV patients.</p><p>References</p><p>Amirayan-Chevillard, N., Tissot-Dupont, H., Capo, C., Brunet, C., Dignat-George, F., Obadia, Y., Gallais, H., and Mege, J. L. (2000) Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients. Clinical and experimental immunology 120, 107-112</p><p>Fraietta, J. A., Mueller, Y. M., Yang, G., Boesteanu, A. C., Gracias, D. T., Do, D. H., Hope, J. L., Kathuria, N., McGettigan, S. E., Lewis, M. G., Giavedoni, L. D., Jacobson, J. M., and Katsikis, P. D. (2013) Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. PLoS Pathog 9, e1003658</p><p>Lau, S. L., Yuen, M. L., Kou, C. Y., Au, K. W., Zhou, J., and Tsui, S. K. (2012) Interferons induce the expression of IFITM1 and IFITM3 and suppress the proliferation of rat neonatal cardiomyocytes. Journal of cellular biochemistry 113, 841-847</p><p>Stone, S. F., Price, P., Keane, N. M., Murray, R. J., and French, M. A. (2002) Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 3, 21-27</p></body></sub-article></article>